Quinoline Compound Scavenging Toxic Aldehydes in Pharmaceutical Formulations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective treatments for various disorders associated with toxic aldehyde toxicity, which are implicated in neurological, autoimmune, inflammatory, and ocular conditions, among others, as current therapies are inadequate in managing these conditions effectively.
Innovation Solution
Pharmaceutical compositions comprising a quinoline compound or its pharmaceutically acceptable salt, which are administered to reduce levels of toxic aldehydes and treat conditions such as inflammatory disorders, ocular diseases, and other systemic or localized conditions by scavenging escaped retinaldehyde and reducing the formation of toxic compounds like A2E, thereby mitigating the progression of diseases like AMD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to manage aldehyde-related disorders, then treatment is provided for some conditions, but the therapies are inadequate and fail to effectively manage neurological, autoimmune, inflammatory, and ocular conditions
Solution Approach 1:
The patent applies universality by developing a single quinoline compound that can treat multiple aldehyde-related disorders across different organ systems (neurological, ocular, inflammatory, autoimmune). The compound serves multiple therapeutic functions by scavenging various toxic aldehydes (MDA, 4-HNE, glyoxal, methylglyoxal, retinaldehyde) that are implicated in diverse conditions including AMD, Parkinson's disease, psoriasis, and inflammatory bowel disease, thereby providing a universal treatment approach for aldehyde toxicity.
2Object-affected harmful factors
If quinoline compounds are administered to scavenge toxic aldehydes, then aldehyde levels are reduced and disease progression is mitigated, but the compounds must achieve sufficient bioavailability and tissue penetration to be effective
Solution Approach 1:
The patent applies parameter changes by optimizing the quinoline compound's chemical structure (with specific R1-R8 substituents) to achieve appropriate pharmacokinetic parameters including bioavailability, half-life, and tissue distribution. The compound is designed to maintain sufficient plasma concentrations and penetrate target tissues (retina, brain, inflamed tissues) at effective doses ranging from 1 mg to 2000 mg, with optimal ranges of 10-600 mg, thereby ensuring adequate drug concentration at target sites to scavenge toxic aldehydes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The quinoline compound compositions effectively reduce toxic aldehyde levels, thereby treating and preventing a wide range of conditions including AMD, inflammatory bowel disease, psoriasis, and other ocular and systemic disorders, offering a comprehensive approach to managing aldehyde-related pathologies.
Implementation Method 1
The quinoline compound compositions effectively reduce toxic aldehyde levels, thereby treating and preventing a wide range of conditions including AMD... by scavenging escaped retinaldehyde and reducing the formation of toxic compounds like A2E
Data Source
AI summary
The present invention relates to pharmaceutical compositions and unit dosage forms comprising a quinoline compound, or a pharmaceutically acceptable salt thereof, which are useful for treatment of a disease, disorder, or condition such as inflammatory diseases, respiratory diseases, organ diseases, viral infections, and sequelae and associated conditions such as acute respiratory distress syndrome.